B ACUTE LYMPHOBLASTIC LEUKEMIA WITH T(9;22)(Q34.1;Q11.2); BCR-ABL1
Clinical trials for B ACUTE LYMPHOBLASTIC LEUKEMIA WITH T(9;22)(Q34.1;Q11.2); BCR-ABL1 explained in plain language.
Never miss a new study
Get alerted when new B ACUTE LYMPHOBLASTIC LEUKEMIA WITH T(9;22)(Q34.1;Q11.2); BCR-ABL1 trials appear
Sign up with your email to follow new studies for B ACUTE LYMPHOBLASTIC LEUKEMIA WITH T(9;22)(Q34.1;Q11.2); BCR-ABL1, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Major trial tests new drug combo in fight against adult leukemia
Disease control OngoingThis study is for adults newly diagnosed with a specific type of acute lymphoblastic leukemia (ALL) called BCR-ABL-positive. It compares the current standard treatment (chemotherapy plus targeted pills) against a newer approach that swaps some chemotherapy for an immunotherapy dr…
Matched conditions: B ACUTE LYMPHOBLASTIC LEUKEMIA WITH T(9;22)(Q34.1;Q11.2); BCR-ABL1
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
New hope for seniors battling aggressive blood cancer
Disease control OngoingThis study is testing two different treatment plans for adults aged 65 and older with a type of blood cancer called acute lymphoblastic leukemia (ALL). One plan combines an immunotherapy drug (blinatumomab) with standard chemotherapy. The other plan combines a targeted drug (dasa…
Matched conditions: B ACUTE LYMPHOBLASTIC LEUKEMIA WITH T(9;22)(Q34.1;Q11.2); BCR-ABL1
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:37 UTC
-
New drug combo tested for Tough-to-Treat leukemia
Disease control OngoingThis study is testing a combination of intensive chemotherapy (called Hyper-CVAD) and a targeted drug called ponatinib for adults with a specific type of acute lymphoblastic leukemia (ALL) that involves a genetic change called Philadelphia chromosome or BCR-ABL. The main goal is …
Matched conditions: B ACUTE LYMPHOBLASTIC LEUKEMIA WITH T(9;22)(Q34.1;Q11.2); BCR-ABL1
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC